Article Data

  • Views 471
  • Dowloads 136

Original Research

Open Access

30 years of preventive studies of uterine cervical cancer 1982–2012

  • J.L. Garrido1,*,

1Clinica Hospital of Medical Specialties Chemsa, Panama City, Republic of Panama

DOI: 10.12892/ejgo2647.2015 Vol.36,Issue 3,June 2015 pp.252-254

Published: 10 June 2015

*Corresponding Author(s): J.L. Garrido E-mail: jolgarrido@hotmail.com

Abstract

The studies for the prevention of uterine cervical cancer in Panama City began in a private institute, impelled by the high incidence of cancer. The preventive programs were initiated with the support of the Obstetrics and Gynecology Institute of the University of Padua n Italy. In these studies, we applied the methodological diagnostics of this Institute with certain modifications adapted to our needs. The diagnosis, treatment, and follow-up were carried out under the protocol of the University of Padua. We achieved a diagnosis of oncogenic isk (OR) in 6,411 patients which corresponded to 5,498 cases of human papillomavirus (HPV), 1,150 cases of dysplasia, 210 cases of cancer, and 794 cases of OR. From 2011, polymerase chain reaction (PCR) was also applied with the aim to improve the accuracy f the diagnosis. With this method the prevalence of pathologies were HPV infections both in healthy patients or in patients cured from PV. Patients were treated by means of local destructive treatments (LDT), basically with cryotherapy and cauterization. We can consider hese results as successful prevention and suggest to extend a preventive program to all the population.

Keywords

Oncogenic risk prevention; Cervical cancer: Treatment evolution.

Cite and Share

J.L. Garrido. 30 years of preventive studies of uterine cervical cancer 1982–2012. European Journal of Gynaecological Oncology. 2015. 36(3);252-254.

References

[1] Armstrong E.P.: “Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types". J. Manag. Care Pharm., 16, 217.

[2] World Health Organization: “Fact sheet No. 297: Cancer”. Geneva, updated 2014. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/

[3] “GLOBOCAN 2002 database: summary table by cancer”. Available at: http://globocan.iarc.fr/Default.aspx

[4] Kent A.: “HPV vaccination and testing”. Rev. Obstet. Gynecol., 2010, 3, 33.

[5] “NCCC National Cervical Cancer Coalition”. Available at: http://web.archive.org/web/20080822004150/http://www.nccc-online.org

[6] Lozano R.: “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet, 2012, 380, 2095.

[7] Canavan T.P., Doshi N.R.: “Cervical cancer”. Am. Fam. Physician, 2000, 61, 1369.

[8] Gadducci A., Barsotti C., Cosio S.; Domenici L.; Riccardo Genazzani A.: “Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature”. Gynecol. Endocrinol., 2011, 27, 597. doi:10.3109/09513590.2011.558953

[9] Campbell S., Monga A.: “Gynaecology by Ten Teachers”. 18th ed. London: Hodder Education, 2006.

[10] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[11] Garrido J.L.: “Apporte dela colposcopia di fronte all infezione del HPV puro ed associato alle displasie e cancro”. Congresso LXIX SIGO 1993, 562.

[12] Garrido J.L.: “Screening of cervical cancer: 27 years experience in six Republics of Panama”. Clin. Exp. Obstet. Gynecol., 2012, 39, 343.

[13] Garrido J.L.: “Incidencia patológica de pacientes primerizas al estudio colpo-citológico 1984-1986”. Ginecologia clínica, 1989, 10, 111.

[14] Dexeus S. “CIN Treatments”. Eur. J. Gynaecol. Oncol., 1989, 20, 285.

[15] Machado F.A., Janssens J.P., Michelin M.A., Murta E.F. “Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix”. Clin. Exp. Obstet. Gynecol., 2012, 39, 27.

[16] Michelin M.A., Murta E.F.: “Potential therapeutic vaccine strategic and relevance of the immune system in uterine cervical cancer”. Eur. J. Gynaecol. Oncol., 2008, 29, 10.

[17] Deligeoroglou E., Christopoulos P., Aravantinos L., Papadias K. “Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review”. Eur. J. Gynaecol. Oncol., 2009, 30, 128.

[18] Agnantis N.J., Sotiriadis A., Paraskevaidis E.: “The current status of HPV DNA testing”. Eur. J. Gynaecol. Oncol., 2003, 24, 351.

[19] Christopoulos P., Papadias K., Panoulis K., Deligeoroglou E.: “Human papillomavirus in adolescence”. Clin. Exp. Obstet. Gynecol., 2009, 35, 248

[20] Garrido J.L.: “Comparative findings of oncogenic cervical risk and its follow-up in two different periods 1982-1999 and 2000-2010”. Eur. J. Gynaecol. Oncol., 2010, 31, 559.

[21] Tuncer Z.S., Boyraz G., Sahin N., Alp A.: “Distribution of human papillomavirus types in Turkish women”. Eur. J. Gynaecol. Oncol., 2012, 33, 204.

[22] Brinkman J.A., Caffrey A.S., Muderspach L.I., Roman L.D., Kast W.M.: “The impact of anti HPV vaccination on cervical cancer: consequences for clinical management”. Eur. J. Gynaecol. Oncol., 2005, 26, 129.

[23] Szarewski A.: “Prophylactic HPV vaccines”. Eur. Gynaecol. Oncol., 2007, 38, 165.

[24] Syrjanen K.: “Persistent high risk human papillomavirus HPV infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation non 16/18 prophylactic HPV vaccines”. Eur. J. Gynaecol. Oncol., 2011, 32, 17.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top